Dong, Wei
Xia, Zeyu
Chai, Zehua
Qiu, Zhidong
Wang, Xuehong
Yang, Zebin
Wang, Junnan
Zhang, Tingrui
Zhang, Qinqin
Jin, Junfei
Funding for this research was provided by:
Natural Science Foundation of Guangxi Province (2020GXNSFDA238006)
Special Fund of the Central Government Guiding Local Scientific and Technological Development by Guangxi Science and Technology Department (ZY21195024)
Medical High Level Talents Training Plan in Guangxi (G202002005)
Science and Technology Planned Project in Guilin (20210102-1)
Guangxi Distinguished Experts Special Fund (2019B12)
Construction Fund of Guangxi Health Commission Key Laboratory of Basic Research in Sphingolipid Metabolism Related Diseases (ZJC2020005)
Construction Fund of Key Disciplines of Medical and Health in Guangxi (2021-8-4-3)
Article History
Received: 13 May 2022
Accepted: 20 November 2022
First Online: 6 December 2022
Declarations
:
: The research involving human plasma sEVs was performed in accordance with the Declaration of Helsinki, and plasma samples from controls and patients with HCC were collected at the Affiliated Hospital of Guilin Medical University (Guangxi, China) after written informed consent was obtained from the patients and their families (#YJSL2021129) and was approved by the Institutional Review Board of the Affiliated Hospital of Guilin Medical University (Guangxi, China).
: Not applicable.
: The authors declare that they have no competing interests.